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Sophie Peresson6, Sophie O’Kelly7, Ana Rito8 and Laura Webber1*Abstract
Background: The majority of chronic disease is caused by risk factors which are mostly preventable. Effective
interventions to reduce these risks are known and proven to be applicable to a variety of settings. Chronic disease
is generally developed long before the fatal outcome, meaning that a lot of people spend a number of years in
poor health. Effective prevention measures can prolong lives of individuals and significantly improve their quality of
life. However, the methods to measure cost-effectiveness are a subject to much debate. The Economics of Chronic
Diseases project aims to establish the best possible methods of measuring cost-effectiveness as well as develop
micro-simulation models apt at projecting future burden of chronic diseases, their costs and potential savings after
implementation of cost-effective interventions.
Method: This research project will involve eight European countries: Bulgaria, Finland, Greece, Lithuania, The
Netherlands, Poland, Portugal and the United Kingdom (UK). A literature review will be conducted to identify
scientific articles which critically review the methods of cost-effectiveness. Contact will be made health economists
to inform and enrich this review. This evidence will be used as a springboard for discussion at a meeting with key
European stakeholders and experts with the aim of reaching a consensus on recommendations for cost-effectiveness
methodology. Epidemiological data for coronary heart disease, chronic kidney disease, type 2 diabetes and chronic
obstructive pulmonary disease will be collected along with data on time trends in three major risk factors related to
these diseases, specifically tobacco consumption, blood pressure and body mass index. Economic and epidemiological
micro-simulation models will be developed to asses the future distributions of risks, disease outcomes, healthcare costs
and the cost-effectiveness of interventions to reduce the burden of chronic diseases in Europe.
Discussion: This work will help to establish the best methods of measuring cost-effectiveness of health interventions
as well as test a variety of scenarios to reduce the risk factors associated with selected chronic diseases. The modelling
projections could be used to inform decisions and policies that will implement the best course of action to curb the
rising incidence of chronic diseases.
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The last millennium was characterised by a worldwide
epidemiological transition, whereby chronic diseases
overtook once predominant infectious diseases as the
leading cause of morbidity and mortality [1]. In Europe
87% of all deaths occur due to chronic diseases [2], and
the number of people affected by these diseases is ex-
pected to rise substantially over the next few decades
[3]. Common and preventable risk factors such as hyper-
tension, tobacco use, raised blood glucose, and over-
weight and obesity are the leading causes of major
chronic diseases such as type 2 diabetes, cardiovascular
and respiratory diseases and should therefore be targeted
if the upward trend in chronic disease morbidity and
mortality is to be abated [4].
Rapid increases in chronic diseases impose large human,
social and economic costs, putting additional pressure on
already overstretched health and social care systems. As a
result, searching for cost-effective measures to reduce the
burden of chronic diseases has become an important task
in public health policy. Moreover, the present climate of
austerity across Europe has increased the urgency with
which we must find cost-effective solutions. Population-
wide interventions in combination with interventions tar-
geted to high-risk individuals and groups, may produce
significant shifts in risk factors, which in turn may greatly
reduce the burden of chronic diseases in populations [5].
The World Health Organization (WHO) has estab-
lished a set of “best buys” for interventions that are
known to be effective, feasible and affordable in reducing
the major risk factors of chronic diseases [5]. On a popula-
tion level such interventions include ban on smoking in
public places, increasing taxes on tobacco and alcohol,
and raising public awareness on benefits of a healthy diet
and physical activity [5]. In addition to population-wide
approaches, screening and pharmacological treatment of
individuals who are at high risk of a chronic disease can
considerably improve the outcomes, especially when com-
bined with lifestyle interventions. For example, a regimen
of aspirin, statins and blood pressure lowering agents can
significantly reduce the risk of vascular events in people at
high risk of cardiovascular disease and, alongside smoking
cessation, is considered a “best buy” [5].
The WHO endorsement of several types of interven-
tions is generally acknowledged as good practice even if
methodological challenges in regards to the methods of
measuring the cost-effectiveness of interventions remain.
Firstly, different guidelines and cut-off levels of what is
considered cost-effective as well as differences in dis-
counting rates exist across different countries making it
difficult to compare the cost-effectiveness of identical or
similar interventions. Secondly, the cost-effectiveness of
the same interventions varies considerably according to re-
gional or national contexts and population characteristics[6]. Thirdly, research and policy processes may be hindered
by the scarcity of economic and epidemiological data re-
quired for cost-effectiveness analysis. These challenges re-
duce the transferability of interventions and the ability to
compare their effectiveness across different settings.
Good health benefits the whole of the society and is
essential for economic and social development [7]. How-
ever, health is unevenly distributed both between and
within countries. Evidence shows that in many countries
the gap in health outcomes between the highest and the
lowest social strata has increased in recent years [8]. In
Europe, these inequalities are likely to increase further
as the health effects of the 2008 economic crisis have
started to emerge in several countries [9]. People in
lower education, employment and/or income systematic-
ally experience higher chronic disease morbidity and
mortality levels [10]. Measures to halt and reverse rising
trends in chronic diseases could and must play an im-
portant role in reducing health inequalities.
The Economics of Chronic Diseases (EConDA) project
addresses the issues outlined above by examining the
cost-effectiveness of interventions to prevent, screen and
treat four major chronic diseases: coronary heart disease
(CHD), type 2 diabetes, chronic kidney disease (CKD)
and chronic obstructive pulmonary disease (COPD). The
project has two key aims. The first aim is to aid EU Mem-
ber States in reviewing methods used assessing the cost-
effectiveness of interventions and establishing agreement
on general principles for good practice in cost-effectiveness
analysis based on effective chronic disease interventions.
Following the agreement, the second aim is to develop eco-
nomic and epidemiological demonstration models to ad-
dress cost-effectiveness of various interventions for chronic
disease prevention, as well as to demonstrate differential
effects of interventions on various population sub-groups.
The models will examine the effect of interventions on
the occurrence of selected chronic diseases and their
outcomes. In particular, they will assess the effect of
cost-effective interventions on the prevalence of risk fac-
tors such as hypertension, body mass index (BMI) and
smoking and the resulting change in incidence of and
mortality from the four selected diseases.
Methods
Eight associated partner organisations and ten collabor-
ating partner organisations are involved in the project
and eight European countries (Bulgaria, Finland, Greece,
Lithuania, the Netherlands, Poland, Portugal and the
UK) will be studied. The range of countries was chosen
to provide a geographical spread and to examine the im-
pacts of economic and health systems differences in
feasibility and applicability of interventions. The work is
planned to be concluded in two and a half years, starting
in April 2013 and ending September 2015.
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4) Building a consensus
5) Development of a disease model
6) Development of a cost-effectiveness model
7) Validation of the models
Work on each of the packages will be split between the
eight associated partners with one of the partners leading
on a selected package. The first three will incorporate ad-
ministrative matters, including regular meetings, account-
ability and dissemination of project development stages
and results. Methods of the four remaining work packages
(4–7) are discussed in more detail below.
Consensus building – work package 4
Work package 4 will be implemented in three phases.
Firstly, a literature review will be conducted to identify
the studies which critically assess the methods used to
measure the cost-effectiveness of interventions for the
selected diseases. The results of the review will be used
in shaping the questions of the interviews with leading
health economists.
In the second phase, international health economics ex-
perts will be consulted in order to enrich the review and
gain a deeper understanding of the methods of measuring
cost-effectiveness of chronic disease interventions.
In the third phase, a consensus meeting will be held,
bringing together a group of European experts including
health economists, policy makers and experts from the
European Chronic Disease Alliance. This meeting will
discuss the themes emerging from the first and the sec-
ond phases of this work package and will aim to estab-
lish consensus on which method/s provide the greatest
utility, as well as to address the question of how we
measure the cost-effectiveness and the impact of inte-
grated approaches to chronic disease prevention on
economies.
Consultation with experts and the consensus meeting
will be conducted in line with the European Commission
guidelines for European Commission funded projects
which are underpinned by the EU Charter of the Funda-
mental Rights [11]. Since the experts will be consulted
in their professional capacity as stakeholders in this EU
project the consultations and the consensus meeting are
exempt from ethical approval.
Development of a disease model – work package 5
Work package 5 will include two phases. Firstly, dis-
ease and risk data will be collected by reviewing open
access papers in PubMed and Science Direct databases,supplemented by Google Scholar search. If necessary
additional data will be collected by searching statistical
data bases and reports as well as contacting disease
registries and individual researchers in the field.
For the purpose of this project, epidemiological data
need to be stratified by age groups and sex, socio-
economic groups and where possible should be nationally
representative. We will collect the most recent incidence,
prevalence, mortality, and survival data. In addition, if
available, we will collect country-specific remission and re-
currence data for the selected diseases.
Risk data will be collected in a similar manner. BMI
prevalence data will be collected if, in addition to the
inclusion criteria above, they are categorised according
to the WHO definition: normal weight (<25 kg/m2),
pre-obese (25–29.9 kg/m2), and obese (≥30 kg/m2).
Hypertension data will be included if they are defined
according to WHO criteria of 140 mmHg systolic and/
or 90 mmHg diastolic blood pressure. In addition to
age and sex specific incidence and prevalence, data on
hypertension stages will be included if available. Smok-
ing patterns will be assessed by collecting data on fre-
quency, the length of smoking in years and exposure to
second hand smoke.
Furthermore, we will identify other possible risk fac-
tors for each of the four diseases. The literature asses-
sing the significance of each risk factor will be examined
to determine the inclusion of a risk factor into the
model. The data on relative risks will be taken from clin-
ical trials and meta-analyses and assumed to have world-
wide applicability. Same data collection procedures will
apply to all participating countries.
Secondly, the project will develop a demonstration
micro-simulation model. The model will apply the
methods developed by the National Heart Forum for the
English Government Tackling Obesities enquiry [12,13].
This model has been subsequently applied to other risk
factors and diseases and validated in over 70 countries
both nationally and locally including the US, Russia,
Mexico and Brazil. In short, a dual-module Markov-style
micro-simulation model will be used. Module 1 uses
multi-variate non-linear regression to project risk trends
to 2030. Module 2 utilises a micro-simulation model to
simulate a virtual population and estimate the future in-
cidence, prevalence and mortality of the diseases of
interest.
We will project the trends of hypertension, obesity
and tobacco use to 2030 and estimate the number of se-
lected diseases’ cases related to these risk factors. We
will then test the impact of effective risk interventions
on the future incidence and mortality using several risk
reduction scenarios. As an example, previously tested
scenarios included testing the effect of mean population
BMI reduction by 1% and 5% on the occurrence of
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able to test the effects of reductions in population levels
of hypertension and the effects of increase in smoking
cessation rates.
Development of a cost-effectiveness model – work
package 6
Work package 6 will be implemented in three phases.
Firstly, the data on both direct and indirect costs for
each selected disease will be collected for each of the
eight countries. The process of data collection will be
the same as the disease data collection procedure. Sec-
ondly, the intervention scenarios will be developed using
information collected in work package 4 and the sugges-
tions arising from the further discussion with partners
and experts. Thirdly, following phases one and two an
economic model will be developed. A demonstration
model will enable to test the cost-effectiveness of inter-
ventions to prevent, screen and treat CHD, COPD, type
2 diabetes and CKD.
Validation of the models – work package 7
We will validate the models using the best available data
from one of the eight countries involved in the project.
The model will be able to demonstrate the future health
impact of positive and negative changes in risk factors as
well as indicate the most cost-effective interventions to
reduce the burden of chronic disease. Moreover, the
model will allow for any specified risk reduction or
intervention to be modelled and it could be subse-
quently updated as new data for current or other coun-
tries become available.
This study has been approved by the European Com-
mission Health Programme and the Executive Agency
for Health and Consumers.
Discussion
Rising incidence of chronic diseases poses a great chal-
lenge to health systems across the globe. In Europe,
chronic diseases are the major cause of mortality and
morbidity and the prevalence of chronic diseases is pre-
dicted to continue to rise to 2030 as a result of ageing
populations and an increase in risk factors such as obes-
ity [6]. There are differences in health outcomes both
between and within countries, with people in lower
socio-economic position experiencing higher rates of
chronic diseases [8]. Health inequalities are likely to in-
crease as a result of European financial crisis, which has
put a significant strain on health systems in several
member states.
Inequalities-related losses to health annually account
for 20% of the costs of health care systems in the Euro-
pean Union as a whole, and as long as health inequalities
persist, these losses will continue to accumulate over theyears [10]. Moreover, it has been estimated that at least
80% of all heart disease, stroke and type 2 diabetes and at
least one third of cancer cases are preventable [7]. This
suggests that a significant amount of chronic disease-
related costs could be saved by tackling health inequalities
and by applying preventative measures proven to be cost-
effective. Therefore no government should ignore an op-
portunity of introducing effective health interventions.
This research will make a significant contribution to
new knowledge with respect to reduction of risk factors
for chronic diseases and implementation of public health
programmes. Specifically, the EConDA project will con-
tribute to public health practice in the following ways:
Firstly, it will address issues in measuring the cost-
effectiveness of health interventions and help to estab-
lish consensus on which method/s provide the greatest
utility. This knowledge could be transferred to different
settings and contexts and may aid future decision
making.
Secondly, data availability is one of the limitations
mentioned in many research publications. We will work
closely with the associate partners to collect and synthe-
sise the most recent disease and risk factor data as well
as best available economic data across eight European
countries. Data sources will be listed in an official report
and the outputs of this research will be made available
through scientific publications and a dedicated website
allowing our findings to be employed in further scholarly
and research work.
Thirdly, we will assess the burden of chronic disease
in various population groups, including those shown to
be most at risk. The effectiveness and the cost-
effectiveness of public health interventions to reduce the
risk of chronic diseases will be tested for the different
strata of populations helping to establish the most effect-
ive ways in intervening across different population
groups.
Finally, the developed models will enable to test and
compare a range of scenarios to tackle chronic disease
and can be updated and applied to various settings. The
dynamics between BMI, smoking, hypertension and re-
lated health outcomes is complex, making it difficult to
choose appropriate policy responses. Establishing the
most effective actions against the chronic disease epi-
demic and indicating cost-effective interventions are
paramount in order to address the financial strain and
capacity issues across European health systems. Our
models may be a tool to achieve that.
Limitations of the study
The models present the best possible attempt to test
specific intervention scenarios and to assess the health
outcomes of disease interventions, given the presently
available data. As better data become available in the
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ther and to better capture the disease processes and the
related costs, allowing for a better understanding of how
interventions would affect different population groups
increasing the validity of the results. The current model-
ling project will help to highlight the existing data gaps
and will identify where governments can gain greater
utility of the models by collecting better surveillance
data.
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